Colin Lightfoot

Colin Lightfoot

B.Sc. Biomedical Science, M.Sc. Infection and Immunity

Colin graduated from the University of Chester with a B.Sc. in Biomedical Science in 2020. Since completing his undergraduate degree, he worked for NHS England as an Associate Practitioner, responsible for testing inpatients for COVID-19 on admission.

See more

Recently Colin was a Study Assistant for Perfectus Biomed, where he grew cell lines and viruses for the testing of mainly commercial cleaning products. He recently completed an M.Sc. in Infection and Immunity at The University of Chester, where his main research focus was antibiotic resistance and the possibility of combatting this with bacteriophage therapy.

See less

Articles from Colin

Foundational characterization of a new bat-borne ebolavirus and its potential as a human pathogen

Foundational characterization of a new bat-borne ebolavirus and its potential as a human pathogen

Photoinactivating effect of visible light on viruses

Photoinactivating effect of visible light on viruses

Spectrum of autoantibodies linked to autoimmune diseases in patients with different COVID-19 clinical outcomes

Spectrum of autoantibodies linked to autoimmune diseases in patients with different COVID-19 clinical outcomes

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

The impact of SARS-CoV-2 on lipids

The impact of SARS-CoV-2 on lipids

mRNA vaccine-induced antibodies shown to be more effective in neutralizing SARS-CoV-2 and its variants than natural immunity

mRNA vaccine-induced antibodies shown to be more effective in neutralizing SARS-CoV-2 and its variants than natural immunity

Ensitrelvir, a novel SARS-CoV-2 antiviral

Ensitrelvir, a novel SARS-CoV-2 antiviral

Risk factors for COVID-19 in older adult patients with cancer

Risk factors for COVID-19 in older adult patients with cancer

Single dose of BNT162b2 vaccine after COVID provides 82% reduction in reinfection risk

Single dose of BNT162b2 vaccine after COVID provides 82% reduction in reinfection risk

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time